Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
about
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre studyProfile of certolizumab and its potential in the treatment of psoriatic arthritisInfiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathyTherapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesSynovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritisTumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.Regulation of innate responses during pre-patent schistosome infection provides an immune environment permissive for parasite development.Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.HLA-B27 modulates intracellular growth of Salmonella pathogenicity island 2 mutants and production of cytokines in infected monocytic U937 cells.Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.The cutting edge of spondylarthropathy research in the millennium.Ankylosing spondylitis: introductory comments on its diagnosis and treatment.Juvenile onset spondyloarthropathies: therapeutic aspectsAnti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experienceEtanercept in psoriatic arthritis.Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules.Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune responseImmunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases.Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritisDetailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatmentSynovial Tissue Response to Treatment with TNF Blockers in Peripheral SpondyloarthritisNovel pharmacological approaches in the treatment of psoriasis.Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitisThe effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade.Infliximab in the treatment of ankylosing spondylitis.Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis.How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis.Pathogenesis of ankylosing spondylitis - recent advances and future directions.Management of ankylosing spondylitis with infliximab.Synovial tissue response to treatment in psoriatic arthritis.Synovitis in spondyloarthritides.Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.
P2860
Q22000875-1E38FEA5-5B53-48E5-830C-5FC7028054D7Q22305856-AA4705DC-F71A-486A-ABA9-3E4B1AF060AAQ24804272-FB71B7FB-1ECC-4204-8949-1C5E4A685E31Q24806367-F0342147-4FB6-41F1-9B9E-4741CAAEA2DBQ24816628-7C9D08FE-4136-46C0-B280-BD12225F48FCQ24816905-32829BDC-F7B7-4AE5-9F38-42C1556A32A4Q24817182-595B294E-87A7-438E-B60C-0B104883E7E8Q31036925-90E73C67-9736-42A2-AA94-D097A2FBD142Q31141885-3FA043B6-8B86-45CF-9256-D95C6A0E96BAQ33358541-2BB4B107-E5D7-4F23-AEC2-05D116E912DAQ34217698-194D7CD6-DF77-42EF-ABD2-FB67586390ECQ34560557-AAD52E17-115F-4DFD-A2EF-3456F139A52CQ34580430-A28F3181-D9B2-4E9C-8122-33A16CEC088CQ34967487-924FA1C9-E5BD-4B31-9652-166254FA61A1Q34967520-F3783B80-707D-43DC-8E40-CDF16258FA74Q34967541-FBD0151F-D40C-471A-AE73-5C1D48166BAAQ35116180-BA1EED74-FC30-4B74-A96E-5A665690183AQ35554049-8B77301C-E829-4337-88CB-106FE6C2A496Q35554321-54AF59E4-D78E-46CE-9272-81E5AD98FA4FQ35555451-91808140-2F2D-48C5-869A-F9EA42ABBE79Q35557923-98FACB14-41BD-47D6-905E-602A4D1DCA60Q35637293-504D1D73-AAB3-4EF2-A62F-34BA3E5BD2F7Q35637474-1BD078DF-2841-49DE-83F7-54E1D374A809Q35638455-DB910D11-947E-47D0-A4A8-02C9EB8CC353Q35687019-6846346B-8DE3-42A7-A929-4B24071225F1Q36008673-93E7C64F-6B37-4D24-A1B5-074E89FABFF9Q36173601-47EB10CB-804C-4BD0-9C50-6F70D4365772Q36245798-F33938CD-CCE1-48AC-A138-83EDA2E030C0Q36373315-FF237478-CC75-4D49-A175-F77901ED92B6Q37008829-578E2ED1-C4A3-44B6-A003-6D78AA9ADD38Q37063563-D5F076F9-BB81-4A87-ADDA-9AD08612BB3DQ37191438-9097D822-61F1-48BD-B1A4-F2540C2166F7Q37290474-E21D7DA0-CD7F-4920-B999-5A92E712D962Q38068590-6EDA74BC-F07F-4E46-8917-C4027EA49375Q38120525-9C376A8C-FB18-4B4E-B270-AA0F289D4A61Q38690443-822D145A-352A-41C7-AA7D-8F2BDF48BC63Q38993236-ABF588D3-9022-4B7C-890A-05FA3237E766Q40576433-BEE40E54-2F80-40D1-8D04-F2A962BD6C8EQ40577128-845D668D-5186-4ED5-B7F2-F2CA037DFC1EQ41612327-12AF079F-26E5-4371-95A8-C9A0D4A219F4
P2860
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Immunomodulatory effects of an ...... rom an open-label pilot study.
@en
Immunomodulatory effects of an ...... rom an open-label pilot study.
@nl
type
label
Immunomodulatory effects of an ...... rom an open-label pilot study.
@en
Immunomodulatory effects of an ...... rom an open-label pilot study.
@nl
prefLabel
Immunomodulatory effects of an ...... rom an open-label pilot study.
@en
Immunomodulatory effects of an ...... rom an open-label pilot study.
@nl
P2093
P2860
P1476
Immunomodulatory effects of an ...... rom an open-label pilot study.
@en
P2093
Cuvelier C
De Keyser F
Demetter P
Kruithof E
Mielants H
Van Damme N
Van den Bosch F
P2860
P304
P356
10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B
P577
2001-01-01T00:00:00Z